Loading...
•
Mar 31, 2020
Amneal Q1 2020 Earnings Report
Amneal's Q1 2020 financial performance was marked by increased net revenue and net income.
Key Takeaways
Amneal Pharmaceuticals reported a solid operational and financial performance in Q1 2020, with net revenue of $499 million, a 12% increase compared to Q1 2019. GAAP net income was $115 million, and adjusted EBITDA was $134 million, a 20% increase year-over-year. The company is maintaining its full-year 2020 financial outlook.
Net revenue for Q1 2020 was $499 million, a 12% increase compared to Q1 2019.
GAAP net income was $115 million, compared to a net loss of $48 million in the prior year period.
Adjusted EBITDA was $134 million, a 20% increase compared to the prior year period.
The company is maintaining its full-year 2020 financial guidance.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is maintaining its previously provided 2020 guidance; operating cash flow excludes expected $110 million cash tax refund.
Revenue & Expenses
Visualization of income flow from segment revenue to net income